"Australian medical technology industry bodies are warning that federal budget changes to R&D tax incentives and CGT will hinder local startups. The sector argues that the 10-year limit on R&D tax refunds is incompatible with the long development cycles of medical products. Industry groups are calling for urgent adjustments to ensure the continued viability of Australian biotech and medtech companies."